General Information of Drug (ID: DMJM9LZ)

Drug Name
LB80380 Drug Info
Synonyms
LB80380; UNII-S9I9P4J8IU; LB 80380; S9I9P4J8IU; LB-80380; 441785-26-8; PMCDG dipivoxil; AC1O59EP; SCHEMBL4270816; CHEMBL1652128; ANA-380; DTXSID90196062; J3.616.617G; [[1-[(2-aminopurin-9-yl)methyl]cyclopropoxy]methyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate; [({[(2-Aminopurin-9-yl)methyl]cyclopropoxy}methyl)[(2,2-dimethylpropanoyloxy)methoxy]carbonyloxy]methyl 2,2-dimethylpropanoate; 872968-04-2
Indication
Disease Entry ICD 11 Status REF
Hepatitis B virus infection 1E51.0 Phase 2b [1]
Cross-matching ID
PubChem CID
6480442
CAS Number
CAS 441785-26-8
TTD Drug ID
DMJM9LZ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Entecavir DM7VTQO Hepatitis B virus infection 1E51.0 Approved [2]
Clevudine DMR21Q3 Hepatitis B 1E51 Phase 3 [3]
Pradefovir DM1O0DV Hepatitis virus infection 1E50-1E51 Phase 2 [4]
MIV-210 DM2NF6X Hepatitis B virus infection 1E51.0 Phase 2 [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepatitis B virus Reverse transcriptase (HBV RT) TTS5K1M DPOL_HBVA3 Inhibitor [1]

References

1 2011 Pipeline of LG Life Sciences.
2 Effect of hepatitis B virus reverse transcriptase variations on entecavir treatment response. J Infect Dis. 2014 Sep 1;210(5):701-7.
3 2011 Pipeline of Bukwang.
4 DOI: 10.1128/AAC.01566-05
5 Emerging antivirals for the treatment of hepatitis B